NAD+
50000 mcg · Mon/Wed/Fri
Evidence
- Human Studies
- 12
- Animal Studies
- 100
- Clinical Status
- Off-label
- Confidence
- Low
- Long-Term Safety
- Limited — most human data is short-term, and mostly on oral precursors rather than direct injection
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
NAD+ is a coenzyme central to cellular energy metabolism and DNA repair. Direct injection or IV infusion is studied for raising cellular NAD+ levels as they decline with age; most rigorous human trials actually study oral precursors (NR, NMN) rather than direct NAD+ injection.
Common Protocols
- 50,000–100,000 mcg (50–100 mg) 2–3x/week, subcutaneous or IV
- Injection can cause noticeable flushing/discomfort at higher doses
Side Effects
- Flushing, nausea, or cramping (especially IV/rapid administration)
- Injection site discomfort
Interactions
- Limited formal interaction data; used cautiously alongside other mitochondrial-support compounds
Practical Details
- Cost
- $$
- Typical Vial Size
- 500 mg
- Storage
- Refrigerate after reconstitution; protect from light
Research Links
Energizing/mitochondrial, do not mix with BPC-157 in same syringe